Congratulations to our client, Silexion Therapeutics Ltd., a clinical-stage, oncology-focused biotechnology company, for closing a business combination with Moringa Acquisition Corp, a publicly-traded special purpose acquisition company (SPAC). The shares of the combined company – Silexion Therapeutics Corp – began trading on Nasdaq under the ticker “SLXN”.

Herzog team was led by Ory Nacht and assisted by Michal Herzfeld, Ron Ben-Menachem,Joshua Ravitz, Efrat Tzur, David Azimov and Danielle Janeli, with the support of our tax team, Dr. Ehab Farah and Shachar Porat, among others.

For additional information >> please see the following article